Asymchem

a biocatalysis CDMO whose enzyme-catalysed routes serve steroid and broader API synthesis, supporting the biocatalytic shift from traditional chemical semi-synthesis.

Country: China

Commercial Biocatalysis CDMO

Coverage

	CN	EU	US
therapeutics-platforms	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Capacity	Peptide solid-phase reaction capacity: 45,000L (as of December 31, 2025), expanding to 69,000L by end of 2026; Oligonucleotide capacity: 120 mol (as of December 31, 2025), projected to increase to 180 mol by June 2026; Synthetic biology full-scale production line: 50L to 5,000L; OEB5 facility HPAPI capacity: >500 kg annually	hkexnews.hk
Certification	ISO 14001, S&P Global Sustainability Yearbook Member, EcoVadis Silver (at major sites), cGMP compliant	pharmasource.global
Regulatory approval	US FDA, NMPA, TGA, MFDS, EMA, MHRA, Health Canada inspected/approved	pharmasource.global · asymchem.com
Production site	Manufacturing sites across China, the United States, and the United Kingdom; includes sites in Tianjin, Jilin, Fuxin, and Sandwich, Kent (UK)	hkexnews.hk · www1.hkexnews.hk
Headcount	10,617 employees (as of December 31, 2025)	hpcimedia.com · asymchem.com · hkexnews.hk
Revenue	RMB6,670.18 million (2025)	hkexnews.hk

Independent sources: hkexnews.hk · hpcimedia.com · pharmasource.global · www1.hkexnews.hk

Technologies

Name	Cluster	Risk
Biosynthetic steroids (fermentation & biocatalytic API)	therapeutics-platforms	Low	→
Chemoenzymatic API synthesis (biocatalytic small-molecule manufacturing)	therapeutics-platforms	Low	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.